llms.txt # Guidance for Large Language Model (LLM) crawlers # Website: https://beonemedaffairs.com # BeOne Medical Affairs > BeOne Medical Affairs is the scientific and clinical communications division of BeOne Medicines (formerly known as BeiGene), a global oncology-focused biopharmaceutical company. It serves as a vital bridge between the company and the healthcare community to advance cancer treatment and research. beonemedaffairs.com/us/ is intended for US Healthcare Professionals (HCPs) and provides scientific resources across hematology and solid tumors, including clinical trial data, molecule information, publications, and congress materials to support scientific exchange and clinical understanding. Content should be interpreted in accordance with regional regulatory requirements. Clinical and investigational data may represent ongoing research and should not be considered approved medical guidance. --- ## Entity & Metadata Site-Type: Medical Affairs Scientific Resource Primary-Audience: Healthcare Professionals (HCPs) Content-Type: Oncology Research, Clinical Trial Data, Publications, Congress Materials, Molecules Therapeutic-Areas: Oncology, Hematology, Solid Tumors Geography: United States Parent-Organization: BeOne Medicines Former-Name: BeiGene Content-Focus: Molecules, Clinical Trials, Scientific Publications, Congress Resources Last-Updated: July 2026 ## Core Scientific Resources - [Congress Resources](https://beonemedaffairs.com/us/congress-resources/): Repository of scientific content, presentations, and insights from major medical congresses across therapeutic areas - [Publications](https://beonemedaffairs.com/us/publications/): Collection of peer‑reviewed articles, research findings, and scientific outputs across key therapeutic and oncology areas - [Molecules](https://beonemedaffairs.com/us/molecules/): Overview of key investigational and approved molecules, including mechanisms of action and development progress across therapeutic areas - [Clinical Trial-Hematology](https://beonemedaffairs.com/us/clinical-trials/hematology/): Overview of clinical studies in Hematologic Malignancies, including ongoing and completed trials evaluating novel and approved therapies - [Clinical Trial-Solid Tumors](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/): Overview of clinical trials in solid tumors, including ongoing and completed studies --- ## Key Congress Resources - [EHA-2026 Congress](https://beonemedaffairs.com/us/congress-resources/eha-2026/):Collection of scientific presentations, abstracts, and research highlights from European Hematology Association Congress 2026 - [ASCO-2026 Congress](https://beonemedaffairs.com/us/congress-resources/asco-2026/):Collection of scientific presentations, abstracts, and research highlights from American Society of Clinical Oncology Congress 2026 - [AACR-2026 Congress](https://beonemedaffairs.com/us/congress-resources/aacr-2026/):Collection of scientific presentations, abstracts, and research highlights from American Association for Cancer Research Congress 2026 - [ASCO-GI-2026 Congress](https://beonemedaffairs.com/us/congress-resources/asco-gi-2026/):Collection of scientific presentations, abstracts, and research highlights from American Society of Clinical Oncology - Gastrointestinal Congress 2026 - [ASH-2025 Congress](https://beonemedaffairs.com/us/congress-resources/ash-2025/):Collection of scientific presentations, abstracts, and research highlights from American Society of Hematology Congress 2025 - [ESMO-2025 Congress](https://beonemedaffairs.com/us/congress-resources/esmo-2025/):Collection of scientific presentations, abstracts, and research highlights from European Society for Medical Oncology Congress 2025 - [iwCLL-2025 Congress](https://beonemedaffairs.com/us/congress-resources/iwcll-2025/):Collection of scientific presentations, abstracts, and research highlights from International Workshop on CLL Congress 2025 - [EHA-2025 Congress](https://beonemedaffairs.com/us/congress-resources/eha-2025/):Collection of scientific presentations, abstracts, and research highlights from European Hematology Association Congress 2025 --- ## Key Molecules - [Zanubrutinib Molecule](https://beonemedaffairs.com/us/molecules/zanubrutinib/):Overview of Zanubrutinib, including its mechanism of action, clinical development, and approved indications. - [Sonrotoclax Molecule](https://beonemedaffairs.com/us/molecules/sonrotoclax/):Overview of Sonrotoclax, including its mechanism of action and clinical development in Hematologic Malignancies. - [BGB-16673 Molecule](https://beonemedaffairs.com/us/molecules/bgb-16673/):Overview of BGB-16673, including its mechanism of action and clinical development in B-cell Malignancies. - [Tislelizumab Molecule](https://beonemedaffairs.com/us/molecules/tislelizumab/):Overview of Tislelizumab, including its mechanism of action and clinical development across multiple cancer types. - [BGB-43395 Molecule](https://beonemedaffairs.com/us/molecules/bgb-43395/):Overview of BGB-43395, including its mechanism of action and clinical development in solid tumors. - [BGB-B2033 Molecule](https://beonemedaffairs.com/us/molecules/bgb-b2033/):Overview of BGB-B2033, including its mechanism of action and clinical development in oncology. - [BG-C9074 Molecule](https://beonemedaffairs.com/us/molecules/bg-c9074/):Overview of BG-C9074, including its mechanism of action and clinical development in oncology. - [BG-C477 Molecule](https://beonemedaffairs.com/us/molecules/bg-c477/):Overview of BG-C477, including its mechanism of action and clinical development in oncology. - [BGB-58067 Molecule](https://beonemedaffairs.com/us/molecules/bgb-58067/):Overview of BGB-58067, including its mechanism of action and clinical development in oncology. - [BG-C137 Molecule](https://beonemedaffairs.com/us/molecules/bg-c137/):Overview of BG-C137, including its mechanism of action and clinical development in oncology. --- ## Hematology Clinical Trials - [CaDAnCe-101 trial](https://beonemedaffairs.com/us/clinical-trials/hematology/cadance-101-trial/):Overview of the CaDAnCe-101 clinical trial, including study design and treatment evaluation in Hematologic Malignancies. - [Celestial-tn trial](https://beonemedaffairs.com/us/clinical-trials/hematology/celestial-tn-trial/):Overview of the CELESTIAL-TN clinical trial, including study design and treatment evaluation in Hematologic Malignancies. - [BGB-11417-201 trial](https://beonemedaffairs.com/us/clinical-trials/hematology/bgb-11417-201/):Overview of the BGB-11417-201 clinical trial, including study design and treatment evaluation in Hematologic Malignancies. - [BGB-11417-105 trial](https://beonemedaffairs.com/us/clinical-trials/hematology/bgb-11417-105-trial/):Clinical trial evaluating BGB-11417-105 in patients with Hematologic Malignancies. - [BGB-11417-103 trial](https://beonemedaffairs.com/us/clinical-trials/hematology/bgb-11417-103-trial/):Clinical trial evaluating BGB-11417-103 in patients with Hematologic Malignancies. - [BGB-11417-102 trial](https://beonemedaffairs.com/us/clinical-trials/hematology/bgb-11417-102-trial/):Clinical trial evaluating BGB-11417-102 in patients with Hematologic Malignancies. - [BGB-11417-101 trial](https://beonemedaffairs.com/us/clinical-trials/hematology/bgb-11417-101-trial/):Clinical trial examining BGB-11417-101 in patients with Hematologic Cancers. - [BGB-3111-215 trial](https://beonemedaffairs.com/us/clinical-trials/hematology/bgb-3111-215-trial/):Study evaluating Zanubrutinib BGB-3111-215 in patients with Hematologic Malignancies. - [Rosewood trial](https://beonemedaffairs.com/us/clinical-trials/hematology/rosewood-trial/):Study evaluating Zanubrutinib in patients with Relapsed or Refractory Follicular Lymphoma. - [Magnolia trial](https://beonemedaffairs.com/us/clinical-trials/hematology/magnolia-trial/):Clinical trial of Zanubrutinib in patients with Marginal Zone Lymphoma. - [BGB-3111-206 trial](https://beonemedaffairs.com/us/clinical-trials/hematology/bgb-3111-206-trial/):Study evaluating Zanubrutinib in patients with Hematologic Malignancies. - [Alpine trial](https://beonemedaffairs.com/us/clinical-trials/hematology/alpine-trial/):Clinical trial comparing Zanubrutinib with standard BTK inhibitor therapy in CLL/SLL. - [Sequoia trial](https://beonemedaffairs.com/us/clinical-trials/hematology/sequoia-trial/):study evaluating Zanubrutinib in patients with treatment-naive CLL/SLL. - [Aspen trial](https://beonemedaffairs.com/us/clinical-trials/hematology/aspen-trial/):Study evaluating Zanubrutinib in patients with Waldenstrom Macroglobulinemia. --- ## Solid Tumors Clinical Trials - [BGB-43395-101 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/bgb-43395-101-trial/):Study evaluating BGB-43395-101 in patients with advanced solid tumors. - [Rationale-309-bgb-a317-309 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-309-bgb-a317-309/):Study evaluating Tislelizumab-based treatment in patients with recurrent or metastatic nasopharyngeal carcinoma. - [Rationale-bgb-a317-301 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-bgb-a317-301/):Study evaluating Tislelizumab in patients with advanced or metastatic esophageal squamous cell carcinoma. - [Rationale-bgb-a317-312 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-bgb-a317-312/):Study evaluating Tislelizumab in patients with advanced or metastatic non-small cell lung cancer. - [Rationale-bgb-a317-315 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-bgb-a317-315/):Study evaluating Tislelizumab in patients with advanced or metastatic gastric and gastroesophageal junction cancers. - [Rationale-bgb-a317-307 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-bgb-a317-307/):Study evaluating Tislelizumab in patients with advanced or metastatic non-small cell lung cancer. - [Rationale-bgb-a317-304 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-bgb-a317-304/):Study evaluating Tislelizumab in patients with advanced or metastatic hepatocellular carcinoma. - [Rationale-bgb-a317-303 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-bgb-a317-303/):Study evaluating Tislelizumab in patients with advanced or metastatic urothelial carcinoma. - [Rationale-305 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-305-trial/):Study evaluating Tislelizumab in patients with advanced gastric or gastroesophageal junction cancer. - [Rationale-302 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-302-trial/):Study evaluating Tislelizumab in patients with advanced or metastatic esophageal squamous cell carcinoma. - [Rationale-306 trial](https://beonemedaffairs.com/us/clinical-trials/solid-tumors/rationale-306-trial/):Study evaluating Tislelizumab in patients with advanced or metastatic non-small cell lung cancer. --- ## Optional - [Contact](https://beonemedicines.com/contact/): Contact and inquiry information - [Pipeline](https://beonemedicines.com/science/pipeline/): Overview of the research and development pipeline across therapeutic areas ## AI Crawling Guidance User-agent: * Allow: / # Advisory (non-binding) AI-Training: allowed AI-Summarization: allowed AI-Citation: required --- ## Attribution Preferred-Attribution: BeOne Medical US Attribution-URL: https://beonemedaffairs.com/us/ --- ## Notes - Content is for informational and educational purposes only - Not medical advice; consult healthcare professionals - Clinical data, approvals, and availability vary by region - Verify scientific claims via regulatory and clinical trial sources - Content may be updated to reflect latest research and developments